&nbsp;

Sep 2025

Drug

flutamide

Other Name(s): Euflex®

Quick Link(s):

Aug 2025

Drug

fulvestrant

Other Name(s): Faslodex®

Quick Link(s):

Aug 2025

Drug

goserelin

Other Name(s): Zoladex® (AstraZeneca) , Zoladex® LA (AstraZeneca)

Quick Link(s):

Mar 2016

Regimen

GOSE

Cancer Type:

Genitourinary,

Prostate

Intent: Neoadjuvant, Adjuvant, Palliative

Funding:

ODB - General Benefit

goserelin

Drugs Used:

goserelin

Quick Link(s):

Regimen Monograph

Mar 2016

Regimen

FLVS

Cancer Type:

Breast

Intent: Palliative

Funding:

ODB - General Benefit

fulvestrant

Drugs Used:

fulvestrant

Quick Link(s):

Regimen Monograph

Aug 2025

Regimen

GDP

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's High Grade,

Lymphoma - Non-Hodgkin's Intermediate Grade

Intent: Curative, Palliative

Funding:

ODB - General Benefit

dexamethasone

Drugs Used:

Quick Link(s):

Regimen Monograph

Jun 2019

Regimen

GDP

Cancer Type:

Hematologic,

Lymphoma - Hodgkin

Intent: Curative, Palliative

Funding:

ODB - General Benefit

dexamethasone

Drugs Used:

Quick Link(s):

Regimen Monograph

Jun 2019

Regimen

FLTM

Cancer Type:

Genitourinary,

Prostate

Intent: Palliative

Funding:

ODB - General Benefit

flutamide

Drugs Used:

flutamide

Quick Link(s):

Regimen Monograph

Oct 2016

Regimen

GOSE

Cancer Type:

Breast

Intent: Adjuvant, Palliative

Funding:

ODB - General Benefit

goserelin

Drugs Used:

goserelin

Quick Link(s):

Regimen Monograph

Sep 2017

Regimen

FC(PO)+R

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

ODB - General Benefit

cyclophosphamide - oral tablets

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma

Drugs Used:

riTUXimab,

fludarabine (Unfunded),

cyclophosphamide,

riTUXimab (subcut)

Quick Link(s):

Regimen Monograph

Aug 2020

Regimen

GDP+RITU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's High Grade,

Lymphoma - Non-Hodgkin's Intermediate Grade

Intent: Curative

Funding:

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma

ODB - General Benefit

dexamethasone

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma

Drugs Used: